



1 SMALL TUBE.
1 MILLION WAYS TO
FIND THE TRUTH¹.

T-SPOT[®] TB

A MOMENT OF TRUTH

TB. TO FIND IT IS TO FIGHT IT.

Tuberculosis (TB) is the world's leading infectious disease killer, affecting millions around the world.² However, TB does not just impact the lives of people in developing countries, it also affects thousands of people in the US every year.³

It is estimated that up to 13 million people in the US are living with latent TB infection.³ About half of those people who develop active TB from latent infection will do so within the first two years of infection.⁴ The risk increases significantly for immunocompromised patients.⁵ The first step in the fight against TB is the use of an accurate test to find it.



1 MILLION

1,000,000 witnesses to tell you if it's TB or not

The T-SPOT.*TB* test is an *in vitro*, interferon-gamma release assay (IGRA) for *Mycobacterium tuberculosis*. An IGRA relies on T cell ability to recognize TB-specific antigens and produce interferon-gamma.

The T-SPOT.*TB* test is designed to maximize clinical utility by optimizing the number of T cells in the assay. Cells are washed to prevent interference from substances or contaminants and counted to ensure that a standard number of cells, 1 million, are used in the assay.

The T-SPOT.TB test mitigates the risk that low cell count will impact patient results⁵

This is especially critical in immunocompromised patients, including those with conditions such as HIV/AIDS, diabetes or chronic renal failure, as well as those receiving immunosuppressive therapy. In these patients, disease state or drug treatment may lead to low cell count or low cell function. With the T-SPOT.TB test, every patient gets a test with the same high sensitivity of 95.6%.¹

ISOLATE

Isolate PBMCs

Enriches the desired cell population (T cells) from whole blood

WASH

Wash cells

Enables removal of serum and potentially interfering substances

COUNT

Count cells

Facilitates correction for variations in patient PBMC counts

STANDARDIZE

Standardize cells

Ensures that the required number of cells are used to produce a reportable result



T-SPOT.TB

- Effective in challenging patient populations¹
 - Immunocompromised
 - BCG-vaccinated
- The only TB test with sensitivity and specificity > 95%¹
 - Sensitivity: 95.6%
 - Specificity: 97.1%
- FDA-approved borderline zone provides increased test resolution for results around the cut-off point^{6,7}
- Requiring only a single visit and a single blood collection tube¹

Give patients and your community peace of mind with the T-SPOT.TB test.

In the fight against TB, the truth has consequences

With so much at stake, positive or negative, what's vital is getting a result you can trust. The T-SPOT.*TB* test does that job with forensic attention to detail. In fact, no test does more to minimize causes of doubt and maximize accuracy. That matters greatly because, in the fight against TB, the truth has consequences.

The T-SPOT.*TB* test - it's not just a test, it's a moment of truth for TB.

Visit **TSPOT.COM** for more information

REFERENCES:

1. Oxford Immunotec. T-SPOT.*TB* Package Insert PI-TB-US-0001 V7. Abingdon, UK. February 2019
2. WHO. Global Tuberculosis Report 2019. Available at: https://www.who.int/tb/publications/global_report/en/ [Accessed March 2020]
3. CDC. Data and Statistics. September 2019. Available at: <https://www.cdc.gov/tb/statistics/default.htm> [Accessed January 2020]
4. CDC. Fact Sheets. October 2014. Available at: <https://www.cdc.gov/tb/publications/factsheets/general/ltbiandactivetb.htm> [Accessed January 2020]
5. Lai et al. *Diagn Microbiol Infect Dis* 2011;71:139-143
6. Rego K, Pereira K, MacDougall J, Cruikshank W. Utility of the T-SPOT®.*TB* test's borderline category to increase test resolution for results around the cut-off point. *Tuberculosis*. 2018;108:178-185. doi:10.1016/j.tube.2017.12.005.
7. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K, IGRA Expert Committee, Centers for Disease Control and Prevention (CDC). Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. *MMWR Recomm Rep*. 2010;59(RR-5):1-25.

T-SPOT®.TB

 **Oxford
Immunotec**

T-SPOT and the Oxford Immunotec logo are registered trademarks of Oxford Immunotec Ltd.
©2020 Oxford Immunotec. All rights reserved. TB-US-LP-MPN366-0001 V1